274 related articles for article (PubMed ID: 35899413)
41. The influence of gut microbiota on drug metabolism and toxicity.
Li H; He J; Jia W
Expert Opin Drug Metab Toxicol; 2016; 12(1):31-40. PubMed ID: 26569070
[TBL] [Abstract][Full Text] [Related]
42. Pharmacomicrobiomics informs clinical pharmacogenomics.
Katsila T; Balasopoulou A; Tsagaraki I; Patrinos GP
Pharmacogenomics; 2019 Jul; 20(10):731-739. PubMed ID: 31368841
[No Abstract] [Full Text] [Related]
43. Pharmacomicrobiomics-Guided Precision Oncology: A New Frontier of P4 (Predictive, Personalized, Preventive, and Participatory) Medicine and Microbiome-Based Therapeutics.
Arga KY; Attia H; Aziz RK
OMICS; 2024 Jan; 28(1):5-7. PubMed ID: 38190279
[TBL] [Abstract][Full Text] [Related]
44. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?
Chen F; Wen Q; Jiang J; Li HL; Tan YF; Li YH; Zeng NK
J Ethnopharmacol; 2016 Feb; 179():253-64. PubMed ID: 26723469
[TBL] [Abstract][Full Text] [Related]
45. Challenges of metabolomics in human gut microbiota research.
Smirnov KS; Maier TV; Walker A; Heinzmann SS; Forcisi S; Martinez I; Walter J; Schmitt-Kopplin P
Int J Med Microbiol; 2016 Aug; 306(5):266-279. PubMed ID: 27012595
[TBL] [Abstract][Full Text] [Related]
46. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.
Prokopienko AJ; Nolin TD
Expert Rev Clin Pharmacol; 2018 Jan; 11(1):71-82. PubMed ID: 28905671
[TBL] [Abstract][Full Text] [Related]
47. Population-level Metagenomics Uncovers Distinct Effects of Multiple Medications on the Human Gut Microbiome.
Nagata N; Nishijima S; Miyoshi-Akiyama T; Kojima Y; Kimura M; Aoki R; Ohsugi M; Ueki K; Miki K; Iwata E; Hayakawa K; Ohmagari N; Oka S; Mizokami M; Itoi T; Kawai T; Uemura N; Hattori M
Gastroenterology; 2022 Oct; 163(4):1038-1052. PubMed ID: 35788347
[TBL] [Abstract][Full Text] [Related]
48. Bringing microbiome-drug interaction research into the clinic.
Guthrie L; Kelly L
EBioMedicine; 2019 Jun; 44():708-715. PubMed ID: 31151933
[TBL] [Abstract][Full Text] [Related]
49. Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability.
Tsunoda SM; Gonzales C; Jarmusch AK; Momper JD; Ma JD
Clin Pharmacokinet; 2021 Aug; 60(8):971-984. PubMed ID: 33959897
[TBL] [Abstract][Full Text] [Related]
50. Pharmacomicrobiomics and Drug-Infection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy.
Torres-Carrillo N; Martínez-López E; Torres-Carrillo NM; López-Quintero A; Moreno-Ortiz JM; González-Mercado A; Gutiérrez-Hurtado IA
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069427
[TBL] [Abstract][Full Text] [Related]
51. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?
Doré J; Multon MC; Béhier JM;
Therapie; 2017 Feb; 72(1):21-38. PubMed ID: 28131442
[TBL] [Abstract][Full Text] [Related]
52. Impacts of the Human Gut Microbiome on Therapeutics.
Vázquez-Baeza Y; Callewaert C; Debelius J; Hyde E; Marotz C; Morton JT; Swafford A; Vrbanac A; Dorrestein PC; Knight R
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():253-270. PubMed ID: 28968189
[TBL] [Abstract][Full Text] [Related]
53. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?
Swanson HI
Drug Metab Dispos; 2015 Oct; 43(10):1499-504. PubMed ID: 26261284
[TBL] [Abstract][Full Text] [Related]
54. The potential impact of gut microbiota on your health:Current status and future challenges.
Sirisinha S
Asian Pac J Allergy Immunol; 2016 Dec; 34(4):249-264. PubMed ID: 28042926
[TBL] [Abstract][Full Text] [Related]
55. Cross talk between drug-resistant epilepsy and the gut microbiome.
Holmes M; Flaminio Z; Vardhan M; Xu F; Li X; Devinsky O; Saxena D
Epilepsia; 2020 Dec; 61(12):2619-2628. PubMed ID: 33140419
[TBL] [Abstract][Full Text] [Related]
56. The gut microbiome in psychiatry: A primer for clinicians.
Van Ameringen M; Turna J; Patterson B; Pipe A; Mao RQ; Anglin R; Surette MG
Depress Anxiety; 2019 Nov; 36(11):1004-1025. PubMed ID: 31356715
[TBL] [Abstract][Full Text] [Related]
57. Engineering the Gut Microbiome for Treatment of Obesity: A Review of Current Understanding and Progress.
Lim YY; Lee YS; Ooi DSQ
Biotechnol J; 2020 Oct; 15(10):e2000013. PubMed ID: 32663372
[TBL] [Abstract][Full Text] [Related]
58. Gut metabolome meets microbiome: A methodological perspective to understand the relationship between host and microbe.
Lamichhane S; Sen P; Dickens AM; Orešič M; Bertram HC
Methods; 2018 Oct; 149():3-12. PubMed ID: 29715508
[TBL] [Abstract][Full Text] [Related]
59. Core gut microbial communities are maintained by beneficial interactions and strain variability in fish.
Kokou F; Sasson G; Friedman J; Eyal S; Ovadia O; Harpaz S; Cnaani A; Mizrahi I
Nat Microbiol; 2019 Dec; 4(12):2456-2465. PubMed ID: 31548685
[TBL] [Abstract][Full Text] [Related]
60. Crohn's Disease, Host-Microbiota Interactions, and Immunonutrition: Dietary Strategies Targeting Gut Microbiome as Novel Therapeutic Approaches.
Núñez-Sánchez MA; Melgar S; O'Donoghue K; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Ruiz-Alcaraz AJ; Ramos-Molina B
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
